Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported R&D Expense of $4.05 million for fiscal year 2025.
Shuttle Pharmaceuticals Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.05M | +12.0% |
| 2024 | $3.62M | +2.9% |
| 2023 | $3.52M | +206.2% |
| 2022 | $1.15M | +12.4% |
| 2021 | $1.02M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $943.5K | -32.6% | -8.0% |
| June 30, 2025 | $1.03M | +58.8% | -34.8% |
| March 31, 2025 | $1.57M | +168.5% | +12.4% |
| September 30, 2024 | $1.40M | +34.0% | +116.9% |
| June 30, 2024 | $645.7K | -23.1% | +10.2% |
| March 31, 2024 | $586.1K | -36.4% | -43.9% |
| September 30, 2023 | $1.05M | +56.2% | +24.5% |
| June 30, 2023 | $839.7K | +901.2% | -8.9% |
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +12.0% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Shuttle Pharmaceuticals Holdings, Inc.’s r&d expense has grown by 296.8% (from $1.02 million to $4.05 million).
- The most recent figure is from Shuttle Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: